16Cost-effectiveness, funding & access
Most of the people who would benefit from a cochlear implant never get one. That is not mainly a story of strict clinical criteria but of access: of the large population with severe-to-profound hearing loss, only a small fraction are ever referred, assessed and implanted. The leaks are at every stage — patients and even hearing-aid dispensers who do not know implantation exists or whom it serves, assessments done with the wrong materials, and a quiet under-referral that keeps eligible people out of the clinic. When funding is capped, a subtler distortion appears: financial pressure biases selection toward the 'most obvious' candidates and squeezes out borderline patients who would still gain. None of this is justified by the economics, which are strongly favourable. This module argues that widening access, not just refining criteria, is part of candidacy.
TThe under-referral gap
The gap is quantifiable. Tens of millions report significant hearing difficulty and a large number have severe-to-profound loss, yet historically only a small fraction — well under 10% of the eligible population — have ever been implanted. Candidacy, viewed honestly, is as much an access and referral problem as a clinical-criteria one.
CWhy so few reach implantation
The named causes are mundane and fixable: lack of knowledge among hearing-aid consumers and dispensers about what implants do and whom they help; the use of inappropriate pre-implant assessment materials that fail to identify candidates; and low public awareness. Each is a leak in the funnel from “could benefit” to “implanted,” and each is addressable by education and better pathways rather than by changing the audiometric line.
CThe economic case
The economics strongly support implantation. Cost-utility analyses put adult cochlear implantation at roughly $12,847 per quality-adjusted life year — favourable against many accepted medical and surgical interventions — and paediatric implantation is cost-effective too, with downstream educational savings as more implanted children are mainstreamed.[2000][2004] Whatever the funding model, this cost-effectiveness must be estimated so that implantation competes fairly with other healthcare for resources.
CRationing bias
Capped funding introduces a “most obvious candidate” rationing bias: under financial pressure, selection drifts toward the patients expected to gain the most and quietly denies treatment to those expected to gain less — distorting candidacy away from clinical needand toward budget. Recognising this is important, because it means an apparently “objective” threshold can encode a funding constraint. The corrective is to keep candidacy a clinical judgement, fund it on its proven cost-effectiveness, and treat the access gap as a problem to be closed rather than a fact to be accepted.
How should this be interpreted?
What does the large gap between eligible and implanted patients mainly reflect?
What is the 'most obvious candidate' rationing bias?